NERV
Price
$1.76
Change
-$0.04 (-2.22%)
Updated
Aug 8 closing price
Capitalization
12.31M
2 days until earnings call
SVRA
Price
$2.64
Change
+$0.01 (+0.38%)
Updated
Aug 8 closing price
Capitalization
456.29M
One day until earnings call
Interact to see
Advertisement

NERV vs SVRA

Header iconNERV vs SVRA Comparison
Open Charts NERV vs SVRABanner chart's image
Minerva Neurosciences
Price$1.76
Change-$0.04 (-2.22%)
Volume$905
Capitalization12.31M
Savara
Price$2.64
Change+$0.01 (+0.38%)
Volume$434K
Capitalization456.29M
NERV vs SVRA Comparison Chart in %
Loading...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.78B. The market cap for tickers in the group ranges from 58 to 93.98B. VRTX holds the highest valuation in this group at 93.98B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 13%. SPRBD experienced the highest price growth at 9,061%, while BIVI experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -26%. For the same stocks of the Industry, the average monthly volume growth was -60% and the average quarterly volume growth was 87%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -14 (-100 ... +100)

Market Cap

The average market capitalization across the group is 234.3M. The market cap for tickers in the group ranges from 12.31M to 456.29M. SVRA holds the highest valuation in this group at 456.29M. The lowest valued company is NERV at 12.31M.

High and low price notable news

The average weekly price growth across all stocks in the group was -3%. For the same group, the average monthly price growth was 7%, and the average quarterly price growth was -13%. SVRA experienced the highest price growth at 2%, while NERV experienced the biggest fall at -8%.

Volume

The average weekly volume growth across all stocks in the group was -51%. For the same stocks of the group, the average monthly volume growth was -71% and the average quarterly volume growth was -66%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 99
Price Growth Rating: 60
SMR Rating: 99
Profit Risk Rating: 92
Seasonality Score: -19 (-100 ... +100)
VS
NERV vs. SVRA commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a Hold and SVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (NERV: $1.76 vs. SVRA: $2.64)
Brand notoriety: NERV and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NERV: 7% vs. SVRA: 40%
Market capitalization -- NERV: $12.31M vs. SVRA: $456.29M
NERV [@Biotechnology] is valued at $12.31M. SVRA’s [@Biotechnology] market capitalization is $456.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than SVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NERV’s TA Score shows that 2 TA indicator(s) are bullish while SVRA’s TA Score has 5 bullish TA indicator(s).

  • NERV’s TA Score: 2 bullish, 6 bearish.
  • SVRA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SVRA is a better buy in the short-term than NERV.

Price Growth

NERV (@Biotechnology) experienced а -7.97% price change this week, while SVRA (@Biotechnology) price change was +1.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.25%. For the same industry, the average monthly price growth was +6.85%, and the average quarterly price growth was +13.24%.

Reported Earning Dates

NERV is expected to report earnings on Aug 12, 2025.

SVRA is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+0.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SVRA($456M) has a higher market cap than NERV($12.3M). SVRA YTD gains are higher at: -14.007 vs. NERV (-20.778). NERV has higher annual earnings (EBITDA): 8.58M vs. SVRA (-108.24M). SVRA has more cash in the bank: 172M vs. NERV (17.3M). NERV has less debt than SVRA: NERV (0) vs SVRA (29.6M). NERV (0) and SVRA (0) have equivalent revenues.
NERVSVRANERV / SVRA
Capitalization12.3M456M3%
EBITDA8.58M-108.24M-8%
Gain YTD-20.778-14.007148%
P/E Ratio2.15N/A-
Revenue00-
Total Cash17.3M172M10%
Total Debt029.6M-
FUNDAMENTALS RATINGS
NERV vs SVRA: Fundamental Ratings
NERV
SVRA
OUTLOOK RATING
1..100
8943
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6159
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
4685

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (40) in the Biotechnology industry is in the same range as SVRA (70). This means that NERV’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as NERV (100). This means that SVRA’s stock grew similarly to NERV’s over the last 12 months.

SVRA's SMR Rating (98) in the Biotechnology industry is in the same range as NERV (100). This means that SVRA’s stock grew similarly to NERV’s over the last 12 months.

SVRA's Price Growth Rating (59) in the Biotechnology industry is in the same range as NERV (61). This means that SVRA’s stock grew similarly to NERV’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as SVRA (100). This means that NERV’s stock grew similarly to SVRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NERVSVRA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 18 days ago
75%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 12 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WATT0.290.01
+2.25%
Energous Corp
LTRX2.990.02
+0.67%
Lantronix
BSBR4.960.01
+0.20%
Banco Santander (Brasil) SA
APLS24.370.04
+0.16%
Apellis Pharmaceuticals

NERV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DNLI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-1.98%
DNLI - NERV
34%
Loosely correlated
-1.90%
ANAB - NERV
33%
Poorly correlated
+3.24%
IDYA - NERV
32%
Poorly correlated
+3.08%
MLTX - NERV
31%
Poorly correlated
+0.98%
GBIO - NERV
31%
Poorly correlated
-1.20%
More

SVRA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with RCKT. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
+0.38%
RCKT - SVRA
63%
Loosely correlated
N/A
PRTA - SVRA
46%
Loosely correlated
-0.39%
RVMD - SVRA
41%
Loosely correlated
+0.17%
CCCC - SVRA
40%
Loosely correlated
-3.10%
ERAS - SVRA
38%
Loosely correlated
-4.11%
More